Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

Performance

52-Week Range 17.5% below 52-week high

22.70

15.9652W Low 27.5052W High

1 Week 3.4% below 1-week high

21.421W Low 23.491W High

Zai Lab Limited - American Depositary Shares (ZLAB) traded between $15.96 and $27.50 over the past 52 weeks and last traded at $22.70, 17.5% below its 52-week high. Over the past week it ranged between $21.42 and $23.49.

Past 12 Months

-1.5%

-11.4%

+22.7%

+8.2%

+31.0%

-15.2%

1W -$0.34

1M -$2.93

3M +$4.21

6M +$1.71

YTD +$5.37

1Y -$4.05

ZLAB was -15.2% over the past year, +8.2% over six months, +31.0% year to date, -1.5% in the last week.

12 Months vs Market

ZLAB

-15.2%

DIA

+12.7%

SPY

+12.4%

QQQ

+9.7%

IWM

+15.6%

Over the past 12 months ZLAB returned -15.2% versus DIA (Dow) +12.7%, SPY (S&P 500) +12.4%, QQQ (Nasdaq 100) +9.7% and IWM (Russell 2000) +15.6%.

Volume & Liquidity 0.57× 3-mo avg

Today 605,020 3-mo avg 1.1M

997.4K

1.1M

971.6K

YTD

885.0K

887.2K

ZLAB most recently traded 605,020 shares against a 3-month average daily volume of 1.1M.

More News

Zai Lab Announces $250 Million Private Placement

October 22, 2026

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

October 21, 2026

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

October 14, 2026

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

September 29, 2026

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Zai Lab Q2 Earnings Call Highlights ↗

August 07, 2026

Via MarketBeat

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 06, 2026

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 03, 2026

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

June 16, 2026

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

June 08, 2026

Zai Lab (ZLAB) Q1 2026 Earnings Transcript ↗

June 01, 2026

Zai Lab Announces Changes to Senior Leadership Team

May 21, 2026

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

May 11, 2026

Zai Lab Q1 Earnings Call Highlights ↗

May 09, 2026

Via MarketBeat

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

May 07, 2026

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

April 22, 2026

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

April 18, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

April 17, 2026

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

April 01, 2026